Transcript
  • 00:01    |    
    Initial credits
  • 00:20    |    
    Introduction
  • 01:52    |    
    Lou Gehrig's batting average
  • Vitamin E treatment
  • 03:33    |    
    Course of amyotrophic lateral sclerosis (ALS)
  • 06:04    |    
    Hemispheric involvement in ALS
  • 07:27    |    
    Cells in the ventral horn
  • 08:28    |    
    Scientific advances
  • 09:41    |    
    Protein mutation
  • 10:07    |    
    Animal experiments
  • Removal of mutant protein from motor neurons
  • 13:10    |    
    Excitotoxicity experiment
    • Translational medicine
    • Glutamate transporter
    • Ceptriaxone use
  • 18:49    |    
    Neurotrophic factors
    • Neurotrophic subtance use
    • Insulin related growth factor
    • Growth hormone experiment
    • Growth factor intraventricular experiment
  • 29:03    |    
    VEGF treatment
  • 29:49    |    
    Emotional liability
    • Charles Darwin's publication
    • Emotionality in ALS example
    • Positive emotional control
    • Glutamate inhibition drug
    • Liability and depression
    • ALS patient improvement
  • 41:40    |    
    Neuroproteinopathies
  • 43:36    |    
    ALS protein therapies
  • Protein aggregation
  • 46:21    |    
    Abnormal enzymatic activity
  • 46:46    |    
    Antisense oligonucleotides
    • Therapeutic scientific uncertainty
    • Intraventricular delivery of antisense oligos
    • Protein effects
    • Patient experiment
    • Preclinical antisense strategy
  • 54:17    |    
    ALS research team
  • 55:41    |    
    ALS experimental evolution
  • 59:48    |    
    Worlwide ALS projects
  • 01:02:54    |    
    Question and answer period
    • Multiple sclerosis
    • Importance of vitamin D
    • Family markers for ALS
    • ALS cure development sites
    • Alternative treatments to ALS
    • Have you observed SOD mutations in other related diseases?
  • 01:13:43    |    
    Final words
  • 01:14:37    |    
    Final credits


A Survey on Degenerative Diseases of the Central Nervous System

New Media  | 23 de marzo de 2010  | Vistas: 19

About this video

Medical investigations and experimental projects have enabled scientists in many countries to obtain greater and improved data on diseases previously unknown to the medical community; that is the case of amyotrophic lateral sclerosis (ALS).  In this conference, Richard A. Smith, a specialist in this topic, shares some of the main characteristics of this medical condition and describes possible treatments, as well.  He explains its pathological traits and course in the human body through time.  Afterwards, he describes how several trial and research experiments, performed by him in different institutions applying different techniques and approaches, have offered the possibility for more treatments.  Smith explains how ALS influences behavior in patients and how this neural discovery has led to the opportunity of designing an efficient treatment that can extend the patients quality of life.  Finally, he recommends clinicians to always be aware of signs shown by the patients which might help the diagnosis and treatment.



Credits

A Survey on Degenerative Diseases of the Central Nervous Systems
Richard A. Smith

Business School Building, EN-606
Universidad Francisco Marroquín
Guatemala, March 23, 2010

New Media - UFM production.  Guatemala, May 2010
Camera: Joni Vasquez, Jorge Samayoa; digital editing: Adrián Méndez; index and synopsis: Sergio Bustamante; content reviser: Sofía Díaz; publication: Carlos Petz/Daphne Ortiz




Conferencista

Richard A. Smith is the medical director of the Center for…

IDEAS DE LA LIBERTAD

Nuestra misión es la enseñanza y difusión de los principios éticos, jurídicos y económicos de una sociedad de personas libres y responsables.

Universidad Francisco Marroquín